Predictive Oncology Develops New Cancer Models, Shares Surge

Predictive Oncology, Inc. (NASDAQ: POAI) has seen a significant rise in its share price on Tuesday following the announcement of new predictive models aimed at targeting various types of cancer.

The Development: The modern predictive models were created using data derived from 21 unique compounds sourced from the University of Michigan's Natural Products Discovery Core. This collaboration involved rigorous testing of these compounds against several prevalent cancers, including breast, colon, and ovarian cancer.

Employing Predictive Oncology's advanced machine learning platform, the team was able to select the most promising compounds and conduct thorough tests. Out of these, three compounds exhibited strong anti-tumor efficacy across various cancer types, even surpassing the performance of a standard drug. Additionally, a fourth compound showed effectiveness specifically against ovarian and colon cancers, while three other compounds excelled in combating breast, colon, and ovarian cancers.

Dr. Ashu Tripathi, the director of the Natural Products Discovery Core, remarked, "The substantial anti-tumor activity demonstrated by these natural compounds across multiple human tumor types strongly supports further investigation into these and other similar compounds. This is particularly important considering that such promising results were obtained from only about 1% of the NPDC library available for exploration."

Current Market Status: As of the latest reports, Predictive Oncology shares have climbed 66.8%, reaching a price of $1.86, showcasing an impressive surge in investor interest and confidence following these developments.

Image: via Shutterstock

Predictive, Oncology, Cancer